

Anita Giobbie-Hurder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9642060/publications.pdf>

Version: 2024-02-01

45
papers

7,219
citations

172457

29
h-index

289244

40
g-index

46
all docs

46
docs citations

46
times ranked

13113
citing authors

#	ARTICLE	IF	CITATIONS
1	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	27.8	2,112
2	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	27.8	956
3	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	7.1	600
4	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	425
5	Challenges of Guarantee-Time Bias. <i>Journal of Clinical Oncology</i> , 2013, 31, 2963-2969.	1.6	360
6	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	10.7	327
7	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	1.6	178
8	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
9	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971.	3.7	145
10	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	1.6	141
11	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	7.1	131
12	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 3510-3519.	7.0	130
13	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	3.4	114
14	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679.	7.0	110
15	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	9.4	107
16	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1179-1188.	1.6	91
17	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016, 122, 1169-1177.	4.1	87
18	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 1286-1299.	9.4	85

#	ARTICLE	IF	CITATIONS
19	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
20	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
21	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 858-868.	3.4	73
22	BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. <i>Molecular Cell</i> , 2016, 63, 277-292.	9.7	61
23	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	7.0	57
24	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. <i>Cancer</i> , 2015, 121, 4007-4015.	4.1	56
25	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 3041-3050.	2.8	51
26	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
27	ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. <i>Journal of Biological Chemistry</i> , 2018, 293, 11166-11178.	3.4	50
28	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3318-3328.	7.0	45
29	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	3.4	44
30	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
31	Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009, 6, 272-287.	1.6	37
32	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	3.7	36
33	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
34	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
35	Qigong Mind-Body Exercise as a Biopsychosocial Therapy for Persistent Post-Surgical Pain in Breast Cancer: A Pilot Study. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473541989376.	2.0	26
36	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	3.7	23

#	ARTICLE	IF	CITATIONS
37	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991.	3.4	21
38	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016, 2, 217.	7.1	21
39	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 α activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9600-E9609.	7.1	20
40	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
41	Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. <i>Acta Oncologica</i> , 2018, 57, 67-73.	1.8	16
42	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. <i>Cancer</i> , 2021, 127, 700-708.	4.1	2
43	Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of Covid-19 Patients Treated with Intravenous Infusion or Subcutaneous Injection. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	2
44	Risk of Bias and Heterogeneity-Reply. <i>JAMA Oncology</i> , 2017, 3, 858.	7.1	0
45	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0